Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome

NCT ID: NCT05298475

Last Updated: 2022-03-28

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-04-01
• Study Completion Date: 2024-04-01

Brief Summary

A total of 100 patients aged 18-85 years old with a definite diagnosis of ACS were admitted to the Department of Cardiovascular, The First Affiliated Hospital of Nanjing Medical University. These patients had fasting serum low-density lipoprotein (LDL-C) >1.8mmol/L (70mg/dL) and were divided into three groups according to the lipid-lowering regimen used: a total of 50 people in the statin-only group received a daily oral medium-dose statin (atorvastatin 20mg qn or rosuvastatin 10mg qn); a total of 30 people in the statin + one injection group per month received oral atorvastatin 20mg qn or rosuvastatin 10mg qn + once a month, subcutaneous injection of 1 injection of PCSK9 inhibitor each time; the remaining 20 people were divided into statin + two injections per month group, oral atorvastatin 20mg qn or rosuvastatin 10mg qn + twice a month, subcutaneous injection of 1 injection of PCSK9 inhibitor each time. We followed up the blood lipid levels of these patients at different time points (one month,three month, six month), including TC, TG, HDL-C, LDL-C,taking the LDL-C reduction ≥50% from the baseline, LDL-C<1.8mmol/L (70mg/dL), and LDL-C<1.4mmol/L (55mg/dL) as the the compliance standard, the blood lipid compliance rates of the three groups at the 6th month of treatment were calculated respectively. The adverse drug reactions of the patients during follow-up were recorded.

Detailed Description

Purpose:The purpose of this study was to explore the short-term effect of a modified, lower-than-guideline-recommended doses of PCSK9 inhibitors combined with a statin in the treatment of dyslipidemia in Chinese with the acute coronary syndrome (ACS), to provide evidence for the use of this drug in real-world Chinese populations. This study will provide more economical, convenient, and acceptable treatment options.

A total of 100 patients aged 18-85 years old with a definite diagnosis of ACS were admitted to the Department of Cardiovascular, The First Affiliated Hospital of Nanjing Medical University. These patients had fasting serum low-density lipoprotein (LDL-C) >1.8mmol/L (70mg/dL) and were divided into three groups according to the lipid-lowering regimen used: a total of 50 people in the statin-only group received a daily oral medium-dose statin (atorvastatin 20mg qn or rosuvastatin 10mg qn); a total of 30 people in the statin + one injection group per month received oral atorvastatin 20mg qn or rosuvastatin 10mg qn + once a month, subcutaneous injection of 1 injection of PCSK9 inhibitor each time; the remaining 20 people were divided into statin + two injections per month group, oral atorvastatin 20mg qn or rosuvastatin 10mg qn + twice a month, subcutaneous injection of 1 injection of PCSK9 inhibitor each time. We followed up the blood lipid levels of these patients at different time points (one month,three month, six month), including TC, TG, HDL-C, LDL-C, taking the LDL-C reduction ≥50% from the baseline, LDL-C<1.8mmol/L (70mg/dL), and LDL-C<1.4mmol/L (55mg/dL) as the the compliance standard, the blood lipid compliance rates of the three groups at the 6th month of treatment were calculated respectively. The adverse drug reactions of the patients during follow-up were recorded.

Conditions

Acute Coronary Syndrome

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Statin-only group

The patients in this group are treated with medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn).

Group Type: EXPERIMENTAL

Statin

Intervention Type: DRUG

Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)

Low-dose PCSK9 inhibitor group

The patients in this group are treated with medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn) and 1 injection of PCSK9 inhibitor once a month SC.

Group Type: EXPERIMENTAL

Statin

Intervention Type: DRUG

Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)

PCSK9 inhibitor

Intervention Type: DRUG

1 injection of PCSK9 inhibitor once a month SC

Normal-dose PCSK9 inhibitor group

The patients in this group are treated with medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn) and 1 injection of PCSK9 inhibitor twice a month SC.

Group Type: EXPERIMENTAL

Statin

Intervention Type: DRUG

Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)

PCSK9 inhibitor

Intervention Type: DRUG

1 injection of PCSK9 inhibitor twice a month SC

Interventions

Statin

Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)

Intervention Type: DRUG

PCSK9 inhibitor

1 injection of PCSK9 inhibitor once a month SC

Intervention Type: DRUG

PCSK9 inhibitor

1 injection of PCSK9 inhibitor twice a month SC

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Aged 18-85 years, gender unlimited;

2. Diagnosed with acute coronary syndrome;

3. The fasting LDL-C≥1.8mmol/L (70mg/dL);

4. Subjects participated in the study voluntarily and signed informed consent.

Exclusion Criteria

1. Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) > 180 mmHg or diastolic BP (DBP) > 110 mmHg；

2. Last known left ventricular ejection fraction < 30%

3. Known hemorrhagic stroke at any time；

4. Severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73m2 at final screening；

5. Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times；

6. LDL or plasma apheresis within 12 months prior to randomization；

7. Pregnant or lactating women；

8. Severe, concomitant non-cardiovascular disease that is expected to reduce life expectancy to less than 3 years；

9. Patients allergic to PCSK9 inhibitors.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The First Affiliated Hospital with Nanjing Medical University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

Countries

China

Central Contacts

Liansheng Wang

Role: CONTACT

jsyzcxw@163.com

+86 13390787111

Other Identifiers

EPICS-CHACS

Identifier Type: -

Identifier Source: org_study_id